

Kathryn V Papp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7988723/publications.pdf>

Version: 2024-02-01

75
papers

4,022
citations

201575

27
h-index

133188

59
g-index

79
all docs

79
docs citations

79
times ranked

4970
citing authors

#	ARTICLE	IF	CITATIONS
1	Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2022, 9, 255-261.	1.5	4
2	Associations of Stages of Objective Memory Impairment With Amyloid PET and Structural MRI. <i>Neurology</i> , 2022, 98, .	1.5	10
3	Lower novelty-related locus coeruleus function is associated with A β -related cognitive decline in clinically healthy individuals. <i>Nature Communications</i> , 2022, 13, 1571.	5.8	32
4	Association of Emerging A β -Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults. <i>Neurology</i> , 2022, 98, .	1.5	20
5	Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 426-438.	1.2	30
6	Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation. <i>Neurology</i> , 2021, 96, e619-e631.	1.5	45
7	Association of Digital Clock Drawing With PET Amyloid and Tau Pathology in Normal Older Adults. <i>Neurology</i> , 2021, 96, e1844-e1854.	1.5	38
8	Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease. <i>Neurology</i> , 2021, 96, .	1.5	18
9	Association of cortical microstructure with amyloid-A β and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults. <i>Molecular Psychiatry</i> , 2021, 26, 7813-7822.	4.1	17
10	In vivo and neuropathology data support locus coeruleus integrity as indicator of Alzheimer's disease pathology and cognitive decline. <i>Science Translational Medicine</i> , 2021, 13, eabj2511.	5.8	107
11	Validation of the Latin American Spanish version of the face-name associative memory exam in a Colombian Sample. <i>Clinical Neuropsychologist</i> , 2020, 34, 1-12.	1.5	13
12	Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. <i>Alzheimer's and Dementia</i> , 2020, 16, 552-560.	0.4	55
13	Multiple markers contribute to risk of progression from normal to mild cognitive impairment. <i>NeuroImage: Clinical</i> , 2020, 28, 102400.	1.4	8
14	The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 104.	3.0	7
15	Tracking the origin of tau spread in the brain. <i>Alzheimer's and Dementia</i> , 2020, 16, e037501.	0.4	0
16	Repeated memory-based assessments: Implications for clinical trials and practice. <i>Alzheimer's and Dementia</i> , 2020, 16, e038143.	0.4	1
17	The dynamic interplay between longitudinal subjective and objective cognitive decline along the early AD spectrum in the Harvard Aging Brain Study. <i>Alzheimer's and Dementia</i> , 2020, 16, e040260.	0.4	0
18	Hypoconnectivity between locus coeruleus and medial temporal lobe during novelty predicts accelerated A β -related cognitive decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e041323.	0.4	2

#	ARTICLE	IF	CITATIONS
19	Estimating an individual's placement on a theoretical continuum using longitudinal cognitive trajectories: Relationships with longitudinal amyloid and Tau-PET. <i>Alzheimer's and Dementia</i> , 2020, 16, e043566.	0.4	0
20	Are amyloid and tau synergistic? How to interpret an amyloid/tau interaction on cognitive decline in clinically normal adults. <i>Alzheimer's and Dementia</i> , 2020, 16, e044310.	0.4	0
21	Trajectories of decline in cognitively complex everyday activities across the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044787.	0.4	1
22	Identifying and predicting heterogeneity in cognitive decline among individuals with prodromal Alzheimer's disease using a latent class analysis. <i>Alzheimer's and Dementia</i> , 2020, 16, e045829.	0.4	1
23	Distinct contributions of longitudinal tau and amyloid to decline in various cognitive domains in preclinical AD. <i>Alzheimer's and Dementia</i> , 2020, 16, e046075.	0.4	0
24	Surface-based amyloid and tau correlates of digital clock drawing performance. <i>Alzheimer's and Dementia</i> , 2020, 16, e046461.	0.4	0
25	U.S. POINTER (USA). <i>Alzheimer's and Dementia</i> , 2020, 16, e046951.	0.4	8
26	Harmonizing the preclinical Alzheimer cognitive composite for multi-cohort studies. <i>Alzheimer's and Dementia</i> , 2020, 16, e047423.	0.4	2
27	Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 138.	3.0	14
28	Examining Cognitive Decline Across Black and White Participants in the Harvard Aging Brain Study. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 1437-1446.	1.2	18
29	The presubiculum links incipient amyloid and tau pathology to memory function in older persons. <i>Neurology</i> , 2020, 94, e1916-e1928.	1.5	13
30	A computerized version of the Short Form of the Face-Name Associative Memory Exam (FACEmemory®) for the early detection of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 25.	3.0	24
31	Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers. <i>Neurology</i> , 2020, 95, e1312-e1321.	1.5	7
32	Word retrieval across the biomarker-confirmed Alzheimer's disease syndromic spectrum. <i>Neuropsychologia</i> , 2020, 140, 107391.	0.7	17
33	The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. <i>Annals of Neurology</i> , 2019, 85, 181-193.	2.8	171
34	Regional Tau Correlates of Instrumental Activities of Daily Living and Apathy in Mild Cognitive Impairment and Alzheimer's Disease Dementia. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 757-768.	1.2	32
35	Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults. <i>JAMA Neurology</i> , 2019, 76, 542.	4.5	201
36	Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2019, 76, 915.	4.5	512

#	ARTICLE	IF	CITATIONS
37	An UNC5C Allele Predicts Cognitive Decline and Hippocampal Atrophy in Clinically Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1161-1170.	1.2	5
38	Decreased meta-memory is associated with early tauopathy in cognitively unimpaired older adults. <i>NeuroImage: Clinical</i> , 2019, 24, 102097.	1.4	7
39	Tau Accumulation in Clinically Normal Older Adults Is Associated with Hippocampal Hyperactivity. <i>Journal of Neuroscience</i> , 2019, 39, 548-556.	1.7	75
40	Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. <i>Nature Neuroscience</i> , 2018, 21, 424-431.	7.1	198
41	The relationship between recall of recently versus remotely encoded famous faces and amyloidosis in clinically normal older adults. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 121-129.	1.2	11
42	O1â€08â€03: DIGITIZED CLOCK DRAWING (DCTCLOCK TM) PERFORMANCE AND ITS RELATIONSHIP TO AMYLOID AND TAU PET IMAGING MARKERS IN UNIMPAIRED OLDER ADULTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P236.	0.4	1
43	O3â€12â€01: DECREASED METAâ€MEMORY FOR EPISODIC BUT NOT SEMANTIC INFORMATION IS ASSOCIATED WITH EARLY TAUOPATHY IN CLINICALLY NORMAL OLDER ADULTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1050.	0.4	0
44	O3â€04â€03: AMYLOID IS ASSOCIATED WITH GREATER TAU BURDEN IN CLINICALLY NORMAL FEMALES RELATIVE TO MALES: FINDINGS FROM TWO INDEPENDENT COHORTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1019.	0.4	0
45	ICâ€Pâ€159: BRAIN RESILIENCE PROTECTS AGAINST COGNITIVE DECLINE ASSOCIATED WITH ELEVATED AMYLOID BURDEN. <i>Alzheimer's and Dementia</i> , 2018, 14, P134.	0.4	0
46	ICâ€Pâ€147: QUANTIFYING STAGES OF SUBTLE MEMORY IMPAIRMENT IN PRECLINICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P125.	0.4	1
47	Sex, amyloid, and <i>APOE</i> ϵ 4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three wellâ€characterized cohorts. <i>Alzheimer's and Dementia</i> , 2018, 14, 1193-1203.	0.4	169
48	Interactive Associations of Vascular Risk and β -Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals. <i>JAMA Neurology</i> , 2018, 75, 1124.	4.5	165
49	Amyloid Accumulation and Cognitive Decline in Clinically Normal Older Individuals: Implications for Aging and Early Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S633-S646.	1.2	52
50	PET staging of amyloidosis using striatum. <i>Alzheimer's and Dementia</i> , 2018, 14, 1281-1292.	0.4	93
51	A Three-Factor Structure of Cognitive Functioning Among Unimpaired Carriers and Non-Carriers of Autosomal-Dominant Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 107-115.	1.2	9
52	Age-Related Increases in Tip-of-the-tongue are Distinct from Decreases in Remembering Names: A Functional MRI Study. <i>Cerebral Cortex</i> , 2017, 27, 4339-4349.	1.6	14
53	Harvard Aging Brain Study: Dataset and accessibility. <i>NeuroImage</i> , 2017, 144, 255-258.	2.1	107
54	Cued memory decline in biomarker-defined preclinical Alzheimer disease. <i>Neurology</i> , 2017, 88, 1431-1438.	1.5	46

#	ARTICLE	IF	CITATIONS
55	Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β . <i>Alzheimer's and Dementia</i> , 2017, 13, 1004-1012.	0.4	139
56	Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline. <i>Annals of Neurology</i> , 2017, 81, 583-596.	2.8	110
57	Neuroimaging markers associated with maintenance of optimal memory performance in late-life. <i>Neuropsychologia</i> , 2017, 100, 164-170.	0.7	35
58	Cognitive resilience in clinical and preclinical Alzheimer's disease: the Association of Amyloid and Tau Burden on cognitive performance. <i>Brain Imaging and Behavior</i> , 2017, 11, 383-390.	1.1	54
59	Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 668-677.	1.8	160
60	Depressive Symptoms and Tau Accumulation in the Inferior Temporal Lobe and Entorhinal Cortex in Cognitively Normal Older Adults: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 975-985.	1.2	70
61	Cognitive Decline in Preclinical Stage 2 Alzheimer Disease and Implications for Prevention Trials. <i>JAMA Neurology</i> , 2016, 73, 640.	4.5	5
62	Tau positron emission tomographic imaging in aging and early Alzheimer disease. <i>Annals of Neurology</i> , 2016, 79, 110-119.	2.8	778
63	Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals. <i>JAMA Neurology</i> , 2016, 73, 1185.	4.5	52
64	Biomarker validation of a decline in semantic processing in preclinical Alzheimer's disease. <i>Neuropsychology</i> , 2016, 30, 624-630.	1.0	60
65	THE FEASIBILITY OF AT-HOME IPAD COGNITIVE TESTING FOR USE IN CLINICAL TRIALS. <i>Journal of Prevention of Alzheimer's Disease</i> , 2016, 3, 1-5.	1.5	39
66	IC-P-085: Regional Tau PET measures associated with memory performance in clinically normal older individuals. , 2015, 11, P60-P61.		0
67	O4-01-01: Regional Tau PET measures associated with memory performance in clinically normal older individuals. , 2015, 11, P265-P265.		1
68	Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease. <i>Neuropsychologia</i> , 2015, 73, 169-175.	0.7	57
69	IC-P-068: The relationship of cognition, cognitive reserve, and in vivo tau and amyloid burden. , 2015, 11, P51-P51.		1
70	O2-02-03: The relationship of cognition, cognitive reserve, and in vivo tau and amyloid burden. , 2015, 11, P175-P175.		0
71	O2-02-05: Differential declines in letter versus category fluency over 4 years in biomarker-defined preclinical Alzheimer's disease. , 2015, 11, P176-P177.		0
72	Development of a Psychometrically Equivalent Short Form of the Face-Name Associative Memory Exam for use Along the Early Alzheimer's Disease Trajectory. <i>Clinical Neuropsychologist</i> , 2014, 28, 771-785.	1.5	57

#	ARTICLE	IF	CITATIONS
73	O3-07-02: WHITE MATTER BURDEN IN CLINICALLY NORMAL OLDER ADULTS MEDIATES THE RELATIONSHIP BETWEEN AMYLOID BURDEN AND MEMORY FREE RECALL BUT NOT CUED RECALL. , 2014, 10, P221-P222.		0
74	DT-01-02: TEMPORAL NEOCORTICAL TAU DEPOSITION MEASURED WITH PET IS ASSOCIATED WITH LONGITUDINAL DECLINE IN MEMORY PERFORMANCE AMONG CLINICALLY NORMAL ELDERLY. , 2014, 10, P280-P280.		0
75	Measuring Executive Dysfunction Longitudinally and in Relation to Genetic Burden, Brain Volumetrics, and Depression in Prodromal Huntington Disease. Archives of Clinical Neuropsychology, 2013, 28, 156-168.	0.3	22